Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 58

1.

The use of mifepristone in the treatment of Cushing's syndrome.

Carroll T, Findling JW.

Drugs Today (Barc). 2012 Aug;48(8):509-18. doi: 10.1358/dot.2012.48.8.1841299.

PMID:
22916338
2.

The use of the glucocorticoid receptor antagonist mifepristone in Cushing's syndrome.

Castinetti F, Brue T, Conte-Devolx B.

Curr Opin Endocrinol Diabetes Obes. 2012 Aug;19(4):295-9. doi: 10.1097/MED.0b013e32835430bf. Review.

PMID:
22543346
3.

A new therapeutic approach in the medical treatment of Cushing's syndrome: glucocorticoid receptor blockade with mifepristone.

Fleseriu M, Molitch ME, Gross C, Schteingart DE, Vaughan TB 3rd, Biller BM.

Endocr Pract. 2013 Mar-Apr;19(2):313-26. doi: 10.4158/EP12149.RA. Review.

PMID:
23337135
4.

Mifepristone: treatment of Cushing's syndrome.

Sartor O, Cutler GB Jr.

Clin Obstet Gynecol. 1996 Jun;39(2):506-10. Review.

PMID:
8734015
5.

Mifepristone for management of Cushing's syndrome.

Morgan FH, Laufgraben MJ.

Pharmacotherapy. 2013 Mar;33(3):319-29. doi: 10.1002/phar.1202. Epub 2013 Feb 21. Review.

PMID:
23436494
6.

Mifepristone (RU 486) in Cushing's syndrome.

Johanssen S, Allolio B.

Eur J Endocrinol. 2007 Nov;157(5):561-9. Review.

7.

The medical management of Cushing's syndrome.

Morris D, Grossman A.

Ann N Y Acad Sci. 2002 Sep;970:119-33. Review.

PMID:
12381547
8.

Mifepristone: is there a place in the treatment of Cushing's disease?

Carmichael JD, Fleseriu M.

Endocrine. 2013 Aug;44(1):20-32. doi: 10.1007/s12020-012-9846-1. Epub 2012 Nov 29. Review.

PMID:
23192246
9.

Mifepristone: a potential clinical agent based on its anti-progesterone and anti-glucocorticoid properties.

Sun Y, Fang M, Davies H, Hu Z.

Gynecol Endocrinol. 2014 Mar;30(3):169-73. doi: 10.3109/09513590.2013.856410. Epub 2013 Nov 11. Review.

PMID:
24205903
10.

Clinical applications of the antiprogestins.

Kettel LM.

Clin Obstet Gynecol. 1995 Dec;38(4):921-34. Review. No abstract available.

PMID:
8616987
11.

Neuropsychiatric disorders in Cushing's syndrome.

Pereira AM, Tiemensma J, Romijn JA.

Neuroendocrinology. 2010;92 Suppl 1:65-70. doi: 10.1159/000314317. Epub 2010 Sep 10. Review.

12.

Mifepristone. Auxiliary therapeutic use in cancer and related disorders.

Koide SS.

J Reprod Med. 1998 Jul;43(7):551-60. Review.

PMID:
9693404
13.

Role of "old" pharmacological agents in the treatment of Cushing's syndrome.

Ambrogio AG, Cavagnini F.

J Endocrinol Invest. 2016 Sep;39(9):957-65. doi: 10.1007/s40618-016-0462-4. Epub 2016 Apr 16. Review.

14.

Cushing's disease.

Tritos NA, Biller BM.

Handb Clin Neurol. 2014;124:221-34. doi: 10.1016/B978-0-444-59602-4.00015-0. Review.

PMID:
25248590
15.

Drugs in the medical treatment of Cushing's syndrome.

Schteingart DE.

Expert Opin Emerg Drugs. 2009 Dec;14(4):661-71. doi: 10.1517/14728210903413522. Review.

PMID:
19939210
16.

Cushing's syndrome: an update on current pharmacotherapy and future directions.

Creemers SG, Hofland LJ, Lamberts SW, Feelders RA.

Expert Opin Pharmacother. 2015;16(12):1829-44. doi: 10.1517/14656566.2015.1061995. Epub 2015 Jul 1. Review.

PMID:
26133755
17.

[Pharmacologic treatment of Cushing's syndrome].

Díez JJ.

Med Clin (Barc). 1998 Jun 6;110(20):781-96. Review. Spanish. No abstract available.

PMID:
9666420
18.

New avenues in the medical treatment of Cushing's disease: corticotroph tumor targeted therapy.

Fleseriu M, Petersenn S.

J Neurooncol. 2013 Aug;114(1):1-11. doi: 10.1007/s11060-013-1151-1. Epub 2013 May 15. Review.

19.

Medical treatment of Cushing's syndrome: adrenal-blocking drugs and ketaconazole.

Feelders RA, Hofland LJ, de Herder WW.

Neuroendocrinology. 2010;92 Suppl 1:111-5. doi: 10.1159/000314292. Epub 2010 Sep 10. Review.

20.

Pharmacological treatment of hypercortisolism.

Shalet S, Mukherjee A.

Curr Opin Endocrinol Diabetes Obes. 2008 Jun;15(3):234-8. doi: 10.1097/MED.0b013e3282fc7025. Review.

PMID:
18438170

Supplemental Content

Support Center